Abstract
The relation between the cell proliferation marker detected by Ki67 monoclonal antibody and tumour size, node involvement, menopausal status, nuclear oestrogen receptors and disease-free survival has been analysed in 236 consecutive breast cancer patients who presented from December 1986 to October 1989. The patients had a median age of 56 years (26-82) and were followed for a median of 34 months (7-51). Ki67 antigen levels were lower in small tumors and when nuclear oestrogen receptors were positive, but did not correlate with nodal involvement. Preliminary data suggest disease-free survival is longer when Ki67 antigen levels are low.
| Original language | English |
|---|---|
| Pages (from-to) | 33-36 |
| Number of pages | 4 |
| Journal | Breast |
| Volume | 2 |
| Issue number | 1 |
| DOIs | |
| Publication status | Published - 1993 |
ASJC Scopus subject areas
- Obstetrics and Gynaecology
Fingerprint Dive into the research topics of 'Clinical and prognostic usefulness of immunohistochemical determination of Ki67 in breast cancer'. Together they form a unique fingerprint.
Cite this
Gottardi, O., Scanzi, F., Zurrida, S., Bono, A., Majno, M., Colombo, P., Ferrari, M., Gambacocta, M., & Rossi, N. (1993). Clinical and prognostic usefulness of immunohistochemical determination of Ki67 in breast cancer. Breast, 2(1), 33-36. https://doi.org/10.1016/0960-9776(93)90034-D